New Therapeutic Agents in Thrombosis and Thrombolysis, Third Edition

by Freedman; Jane E.

• ISBN13: 9781420069235
• ISBN10: 1420069233
• Edition: 3rd
• Format: Hardcover
• Copyright: 2009-06-24
• Publisher: CRC Press

Summary

As the number of patients with thrombosis and thrombolysis increases, there is a critical need for clinicians to learn the latest scientific discoveries and treatment options. This timely Third Edition is a comprehensive text for cardiologists, hematologists, and pharmacologists in need of a resource on current agent development technology for treating cardiovascular and thromboembolic diseases.New to the Third Edition: a thorough examination of all the agents involved in treating thrombosis chapters on biomarkers, testing, and pharmacogenomics key topics, including new targets for antithrombotics, the development of novel classes of platelet inhibitors, new thrombolytic therapies, and evolving clinical uses of thrombolytics for ischemic stroke and venous thrombosis the hemostatic and thrombotic pathways

Author Biography

Jane E. Freedman is Professor of Medicine, Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, USA. She received her M.D. from Tufts University School of Medicine, Boston, Massachusetts, USA. Dr. Freedman is an Associate Editor of Circulation and has authored or co-authored over 100 scientific publications primarily in the field of thrombosis. Joseph Loscalzo is Hersey Professor of the Theory and Practice of Medicine, Harvard Medical School, and Chairman of the Department of Medicine and Physician-in-Chief, Brigham and Women's Hospital, Boston, Massachusetts, USA. He received his M.D. and Ph.D. in biochemistry from the University of Pennsylvania, Philadelphia, USA. Dr. Loscalzo has received many awards, including the Paul Dudley White Award from the American Heart Association and the Outstanding Investigator Prize from the International Society for Heart Research. He has served as Associate Editor of the New England Journal of Medicine for nine years and is Chair for several boards and committees, including the Research Committee of the American Heart Association. He has authored or co-authored more than 500 scientific publications, has authored or edited 23 books, and holds 27 patents for his work in the field of nitric oxide. Dr. Loscalzo is also Editor of Informa Healthcare's Molecular Mechanisms of Atherosclerosis.

Table of Contents

Series Introduction	p. iii
Preface	p. v
Contributors	p. xi
Overview of the Investigation and Regulation and Thrombosis
Overview of Hemostasis and Fibrinolysis	p. 1
Overview of Platelet-Dependent Thrombosis	p. 9
Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents	p. 19
Pharmacogenomics and Warfarin Anticoagulation	p. 37
Pharmacogenomics of Platelet Inhibitors	p. 49
The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers	p. 67
The Role of Platelet Function Testing in the Development of Platelet Inhibitors	p. 99
The Role of Proteomics and Transcriptomics in the Development of Antithrombotics	p. 117
New Heparins, Thrombin Inhibitors, and Antithrombotics
Overview of New Anticoagulant Drugs	p. 133
Anticoagulants for the Treatment of Venous Thromboembolism	p. 155
Anticoagulation in Acute Coronary Syndromes	p. 171
Anticoagulation in Pregnancy	p. 197
Anticoagulants in Cancer	p. 221
Anticoagulation in Children	p. 237
New Heparins: Synthetic Pentasaccharides	p. 253
Treatment of Heparin-Induced Thrombocytopenia	p. 269
Emerging Links Between Thrombosis, Inflammation, and Angiogenesis: Key Role of Heparin and Low-Molecular-Weight Heparins	p. 289
Oral Direct Factor Xa Inhibitors	p. 307
Direct Thrombin Inhibitors	p. 327
Modulators of the Protein C Pathway	p. 341
Factor IXa Inhibitors	p. 359
Contact-Activation Pathways as Targets for New Anticoagulants	p. 377
New Antiplatelet Agents
Overview of Antiplatelet Therapy	p. 399
Markers of Platelet Function	p. 409
Intravenous Glycoprotein IIb/IIIa Antagonists	p. 429
Inhibitors of Platelet Adhesion: VWF-GP1b/IX and Collagen-GPVI Inhibitors	p. 457
Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel	p. 471
Direct P2Y12 Antagonists	p. 485
Nitric Oxide Donors as Platelet Inhibitors	p. 499
The Interrelationship of Thrombin and Platelets-The Protease-Activated Receptor-1	p. 517
Other Antiplatelet Agents	p. 535
The Combination of Anticoagulants and Platelet Inhibitors Postcoronary Stent Implantation	p. 555
New Thrombolytic Agents and Indications
Overview of Established and New Thrombolytics	p. 563
Thrombolysis of Deep Vein Thrombosis	p. 579
Thrombolysis for Acute Pulmonary Embolism	p. 595
Acute Thrombolysis in Ischemic Cerebrovascular Disease	p. 617
Fibrinolysis for Acute Myocardial Infarction	p. 651
Epilogue: The Evolution of Therapeutic Management of Thrombotic and Cardiovascular Disease	p. 667
Index	p. 671
Table of Contents provided by Ingram. All Rights Reserved.